Answers are grounded in this paper and cite their sources.
Background Parkinson’s disease (PD) is recognized as a multisystem disorder involving central neuroinflammation and peripheral immune dysregulation. Reported alterations in circulating lymphocyte subsets remain inconsistent, owing to small study sizes, heterogeneous marker definitions, and variable reporting of absolute counts versus percentages. Objective To evaluate peripheral lymphocyte subset alterations in PD versus controls, analyzing absolute-count and percentage outcomes separately. Methods Eligible case–control and observational studies reporting peripheral blood lymphocyte data were included. Standardized mean differences (Hedges’ g) for CD3+, CD4+, CD8+, B-cell, CD56+, and NK-cell outcomes were pooled using random-effects meta-analyses. Absolute counts and percentages were analyzed separately, never pooled, and the between-scale difference tested formally. Heterogeneity (Cochran’s Q, I 2 , τ 2 ), subgroup, meta-regression, funnel, leave-one-out, Baujat, and influence analyses were performed where feasible. Results Eighteen studies (1,807 patients; 1,729 controls) were included. After a study-level audit correcting standard-error, interquartile-range, sample-size, and measurement-scale discrepancies, the strongest adaptive finding was a modest, significant CD4+ absolute-count reduction (k = 3; g = −0.40, 95% CI −0.71 to −0.09; p = 0.011; I 2 = 39%). CD8+ absolute counts were also significantly reduced (k = 2; g = −0.40, −0.68 to −0.12; p = 0.005), whereas CD3+ absolute counts met inclusion rules in only one cohort (not pooled). The CD3+ percentage was modestly but significantly reduced (k = 11; g = −0.37; p = 0.025), whereas percentages showed no significant association for CD4+ (g = 0.07; p = 0.615), CD8+ ( p = 0.439), or B cells ( p = 0.203). NK-cell percentage was not significantly altered once repeated within-cohort gating and marker-definition differences were addressed (k = 4; g = 0.12, −0.30 to 0.55; p = 0.572); NK-cell absolute count was positive but non-significant ( k = 2; g = 0.16; p = 0.148), and CD56+ was not poolable after excluding a biologically implausible gate. Several analyses were limited by small study number, heterogeneity, and variable marker definitions. Conclusion PD is associated with peripheral lymphocyte alterations, most notably modest, low-heterogeneity reductions in CD4+ and CD8+ absolute counts and a modest reduction in the CD3+ percentage; the NK-cell percentage increase reported in earlier studies was not reproduced once within-cohort dependence and marker definitions were accounted for. These findings support peripheral immune remodeling and underscore distinguishing counts from percentages and accounting for correlated estimates. Larger, longitudinal studies using standardized flow-cytometry panels are needed to validate these subsets as biomarkers of PD immune dysregulation, severity, and progression.
No takes yet. Share an insight, caveat, or question.
Akhter et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: